Sucampo Pharmaceuticals (NASDAQ: SCMP) is one of 294 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Sucampo Pharmaceuticals to similar businesses based on the strength of its institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Risk and Volatility

Sucampo Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Sucampo Pharmaceuticals’ peers have a beta of 6.61, suggesting that their average stock price is 561% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sucampo Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sucampo Pharmaceuticals $247.08 million $107.68 million -3.21
Sucampo Pharmaceuticals Competitors $473.33 million $171.79 million -7.10

Sucampo Pharmaceuticals’ peers have higher revenue and earnings than Sucampo Pharmaceuticals. Sucampo Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for Sucampo Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sucampo Pharmaceuticals 0 2 4 0 2.67
Sucampo Pharmaceuticals Competitors 725 3161 11785 265 2.73

Sucampo Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 67.46%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.43%. Given Sucampo Pharmaceuticals’ higher possible upside, research analysts plainly believe Sucampo Pharmaceuticals is more favorable than its peers.

Institutional and Insider Ownership

55.4% of Sucampo Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.1% of Sucampo Pharmaceuticals shares are owned by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Sucampo Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sucampo Pharmaceuticals -61.99% 56.58% 15.47%
Sucampo Pharmaceuticals Competitors -5,540.84% -391.69% -42.50%

Summary

Sucampo Pharmaceuticals peers beat Sucampo Pharmaceuticals on 7 of the 13 factors compared.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.